Research and Markets: Evolving Trends in Licensing: Examine Expert Strategies for Building and Retaining Value in Biotechnology Alliances
Research and Markets (http://www.researchandmarkets.com/research/121eac/evolving_trends_in) has announced the addition of Decision Resources, Inc.’s new report “Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances” to their offering.
This report features interviews with top executives and industry experts, who offer insight into current alliances and contribute to a broad perspective on the drivers of current licensing practices.
As the biotechnology industry continues to evolve and mature, many biotech companies are gaining more leverage in negotiating alliances. We analyzed recent deals and interviewed industry executives and experts to gain insight into current alliances and licensing practices. Multiple business and technological factors are converging to reshape the complex biotech-pharma industry landscape.
Get the Answers You Need to Shape Your Strategy
— Rising deal values, evolving deal structures, and increasing competition for quality programs suggest that biotech companies are gaining more bargaining power in negotiating alliances. What factors are influencing current licensing strategies and practices? How are changes in the biotech and pharmaceutical industry affecting deal structures? What deal features are most important in retaining value for the biotech company?
— Facing significant challenges, pharmaceutical companies are incorporating more structures that are advantageous to biotech companies into partnerships. What deal structures characterize recent high-value alliances? How do these features affect each company’s strategic interests? Which biotech companies are negotiating creative deal structures with Big Pharma?
— Big Pharma appears to be regaining interest in collaborating with or acquiring companies with platform technologies. Which biotech companies have platform technologies that interest Big Pharma? What factors make a platform technology valuable to Big Pharma? What are the drivers behind Big Pharma’s interest in platform technology companies?
— With the IPO window effectively closed, M&As provide an appealing exit strategy. What factors influence a company’s decision to use M&A as an exit strategy? How does the current M&A frenzy in biotech affect industry alliances? How can biotech companies protect their value in the event of an acquisition?
— Monetizing intellectual property and technology: Alnylam Pharmaceuticals/Roche, Alnylam Pharmaceuticals/Takeda; high-value, nonexclusive partnerships; RNA interference); nondilutive capital infusion; copromotion and co-commercialization; opt-ins.
— Moving up the strength curve: Targacept/GlaxoSmithKline; Center for Excellence for External Drug Discovery (CEEDD); neuronal nicotinic receptors; risk-share alliance, “Phase II economics.”
— Codevelopment and co-commercialization: Ariad Pharmaceuticals/Merck; deforolimus; 50-50 development and commercialization; copromotion; booking top-line revenue.
— Mergers & acquisitions: Adnexus Therapeutics/Bristol-Myers Squibb; Adnectins; biologics platform; high-value, early-stage deal followed by acquisition; Infinity Pharmaceuticals/MedImmune and AstraZeneca/MedImmune; impact of M&A change-of-control; noncompete provisions.
— Academic licensing: Sublicensing provisions; sharing milestone payments; intellectual property provisions in collaborations.
Key Topics Covered:
— Alnylam/Roche, Alnylam/Takeda: Monetizing a Discovery Platform
— Deal Structures
— Targacept/GlaxoSmithKline: Moving Up the Strength Curve
— Ariad Pharmaceuticals/Merck: Partners in Development and Commercialization
— Adnexus Therapeutics/Bristol-Myers Squibb: Acquired by a Collaborator
— Infinity Pharmaceuticals: When Your Partner Is Acquired
— View from Academia
— Outlook for Biotech Licensing Strategies
— The Evolving Biotech Industry
— The Value of Technology Platforms
— Codevelopment and Co-Commercialization
— Rising Deal Values
— Mergers and Acquisitions
— Changing Industries
— List of Tables
— List of Figures
— Addex Pharmaceuticals
— Adnexus Therapeutics
— Alantos Pharmaceuticals
— Alnylam Pharmaceuticals
— Anacor Pharmaceuticals
— Argenta Discovery
— Ariad Pharmaceuticals
— Array BioPharma
— Astellas Pharma
— Astex Therapeutics
— Avalon Pharmaceuticals
— Biogen Idec
— Boehringer Ingelheim
— Bristol-Myers Squibb
— Cambridge Antibody Technology
— Discovery Partners
— Eli Lilly
— Infinity Pharmaceuticals
— Isis Pharmaceuticals
— Janssen Pharmaceutica
— Johnson & Johnson
— Kosan Biosciences
— Kyowa Hakko
— Massachusetts Institute of Technology
— Merck Serono
— Neurimmune Therapeutics
— Palatin Technologies
— Regulus Therapeutics
— Santaris Pharma
— SGX Pharmaceuticals
— Silence Therapeutics
— Sirna Therapeutics
— Sirtris Pharmaceuticals
— Synta Pharmaceuticals
— Syntonix Pharmaceuticals
— Takeda Pharmaceutical
— Transform Pharmaceuticals
— Tufts University
— University of California, San Francisco
For more information visit http://www.researchandmarkets.com/research/121eac/evolving_trends_in.